Effects of Dapagliflozin and Empagliflozin in Myocardial Dysfunction

Evaluation Effects of Dapagliflozin and Empagliflozin in Nondiabetic Patients with Left Ventricular Systolic Dysfunction following ST Elevation Myocardial Infarction : A Randomized Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20111206008307N45

Enrollment

Registered

2024-02-27

Start date

2024-02-20

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Heart failure. Condition 2: Myocardial infarction. Heart failure ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

Interventions

Intervention 1: Intervention group: Patients will receive 10 mg empagliflozin daily for 40 days in addition to usual treatments. Intervention 2: Intervention group: Patients will receive 10 mg dapagli

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Heart Failure with Reduced Ejection Fraction Aged 18 to 80 years Consented patients

Exclusion criteria

Exclusion criteria: Pregnancy Lactation Liver failure Renal failure (estimated glomerular filtration rate less than 30 ml/min) Patients with a history of taking dapagliflozin or empagliflozin Diabetes mellitus Contraindications of dapagliflozin or empagliflozin Inflammatory and autoimmune diseases Systolic blood pressure less than 100 or more than 180 mm Hg Symptomatic hypotension Malignancy

Design outcomes

Primary

Measure	Time frame
New York Heart Association (NYHA) Functional Classification. Timepoint: At baseline and 40 days after intervention. Method of measurement: Assessment by one cardiologist.	—

Secondary

Measure	Time frame
High-sensitivity C-reactive protein (hs-CRP). Timepoint: At baseline and 40 days after intervention. Method of measurement: Laboratory test.;NT-proBNP. Timepoint: At baseline and 40 days after intervention. Method of measurement: Laboratory test.;Ejection fraction. Timepoint: At baseline and 40 days after intervention. Method of measurement: Echocardiography.;Left ventricular end-diastolic volume. Timepoint: At baseline and 40 days after intervention. Method of measurement: Echocardiography.;Hospitalization due to cardiovascular reasons. Timepoint: Within 40 days after intervention. Method of measurement: Interview.	—

Measure

Time frame

High-sensitivity C-reactive protein (hs-CRP). Timepoint: At baseline and 40 days after intervention. Method of measurement: Laboratory test.;NT-proBNP. Timepoint: At baseline and 40 days after intervention. Method of measurement: Laboratory test.;Ejection fraction. Timepoint: At baseline and 40 days after intervention. Method of measurement: Echocardiography.;Left ventricular end-diastolic volume. Timepoint: At baseline and 40 days after intervention. Method of measurement: Echocardiography.;Hospitalization due to cardiovascular reasons. Timepoint: Within 40 days after intervention. Method of measurement: Interview.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTaher Entezari-Maleki

Tabriz University of Medical Sciences

tentezari@gmail.com+98 41 3335 5983

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026